FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

A patient’s response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait, and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved predictive biomarkers (progra1mmed cell death ligand-1 (PD-L1); microsatellite instability (MSI); tumor mutational bur...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Front Oncol
Главные авторы: Wang, Ye, Tong, Zhuang, Zhang, Wenhua, Zhang, Weizhen, Buzdin, Anton, Mu, Xiaofeng, Yan, Qing, Zhao, Xiaowen, Chang, Hui-Hua, Duhon, Mark, Zhou, Xin, Zhao, Gexin, Chen, Hong, Li, Xinmin
Формат: Artigo
Язык:Inglês
Опубликовано: Frontiers Media S.A. 2021
Предметы:
Oncology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8216110/
https://ncbi.nlm.nih.gov/pubmed/34164344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.683419
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы